Arkolith/Insider Trading/NLTX/Form 4

Patel Priti

Chief Medical OfficerNeoleukin Therapeutics, Inc. (NLTX) · full profile →Form 4 · filed Feb 3, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$9K
Net Open-Market Flow
-$9K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 2, 2023Sell(S)14K$0.60$9K31K
Feb 1, 2023Option exercise(M)35K—$045K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 1, 2023Option exercise(M)35K—$035K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-006881) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML